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Objective: Saliva secretion disorder may appear in patients at any age and represents a serious problem in
interdisciplinary treatment. It is manifested by hyposecretion or hypersecretion of saliva. One of the major groups of
patients who have been diagnosed with saliva secretion disorder includes those treated with neuroleptics. Among
patients taking neuroleptics, schizophrenic patients represent the least cooperative group in terms of doctor-patient
relationship. Schizophrenia is a mental disorder exacerbated by uncontrolled neuroleptic dose reduction or regardless
of applied pharmacotherapy.
Method: This paper presents a clinical case of a 30-year-old schizophrenic patient with saliva secretion problems.
Results: In schizophrenia, thought disorders (TD) and social functioning impairment have a negative impact on
patients’ somatic health care. Saliva hyposecretion and its health consequences, such as parodontitis and caries, are the
reasons why the patients decide to have a dental appointment.
Conclusion: This paper contains important information for dentists, psychiatrists, and psychologists, as it raises an issue
of a proper interdisciplinary care approach provided to schizophrenic patients. It emphasises the importance of
psychoeducation and draws attention to social functioning of mentally ill patients.
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Salivary fluid is an exocrine secretion consisting of
approximately 99% water and a variety of electrolytes
such as sodium, potassium, calcium, chloride, magnesium,
bicarbonate, and phosphate. Also, this fluid contains pro-
teins, represented by enzymes, immunoglobulins and
other antimicrobial factors, mucosal glycoproteins, albu-
mins and some polypeptides, and oligopeptides important
for oral health. The components interact and are re-
sponsible for the various functions attributed to saliva
(Figure 1). Saliva secretion disorder is considered to be
troublesome and affects negatively the patients’ health
status. It is most frequently related to the use of anti-
cholinergics drugs [1,2]. Schizophrenia is one of the
most common disorders in which saliva secretion is
disturbed as a result of antipsychotic pharmacotherapy
[3]. Schizophrenia is a mental disorder which can beCorrespondence: mos.danuta@wp.pl
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unless otherwise stated.characterised by both positive symptoms (delusions
defined as false beliefs and hallucinations defined as
false perceptions) and negative symptoms (flat affect,
apathy, anhedonia) [4]. Impaired social functioning of
schizophrenic patients, manifested by difficulties in
recognising their needs and lower ability to communi-
cate in society, constitutes the main behavioral feature
of schizophrenia [5,6].
Schizophrenic patients do not always care for their
health and personal hygiene, including oral cavity hygiene
[7,8]. Their dental health status is poor as compared with
mentally healthy people. It is also the consequence of
irregular and unhealthy diet and more frequent smoking
habits [9]. According to the study, only 42% of schizo-
phrenic patients brush their teeth regularly (at least twice
a day) [10]. This poor dental health leads to functional
difficulties. Negligence with regards to oral health care
observed in patients suffering from schizophrenia or other
psychotic disorders results from cognitive deficits whichn Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Function of saliva.
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make it difficult for these patients to care for their denti-
tion status.
Antipsychotics and other medications used in the
treatment of schizophrenia, such as antidepressants and
mood stabilizers, may result in saliva secretion disorders
or drug-induced mouth dryness (xerostomia), contribut-
ing to caries development [11]. Moreover, schizophrenic
patients with a history of drug-related adverse effects,
such as life-threatening neuroleptic malignant syndrome
(NMS), or who have undergone electroconvulsive
therapy (ECT) can be more suspicious not only of
psychiatrists but also of other specialists, including
dentists [12].
Case presentation
A 30-year-old schizophrenic patient decided to visit the
dentist office because of a toothache. The patient com-
plained of burning sensation and dryness in her mouth
and sleep disturbances. One week prior to the visit, the
patient had stopped taking antipsychotic drugs pre-
scribed by a psychiatrist, which she had taken at the fol-
lowing doses: aripiprazole 30 mg/day, perazine 100 mg/
day, and carbamazepine 800 mg/day. She admitted to
having taken the drugs irregularly. The patient either
discontinued the treatment for several days or had taken
double doses on subsequent days ‘to feel better faster’.
The patient had poor insight into the illness, did not seea need for regular treatment of schizophrenia, and re-
ported depressive mood caused by ‘chips in the teeth’.
She had a history of neuroleptic malignant syndrome
caused by risperidone treatment, therefore she was un-
willing to take antipsychotic drugs, or she reduced the
dosage by herself, being afraid of adverse events. During
oral cavity and dental examination at the dentist office,
the patient was diagnosed with circular and root caries,
thick dental plaque, oral mucositis in the form of ulcera-
tions, mucosal redness and dryness, as well as spontan-
eous mucosal lacerations. Food residues were also
detected. Silness-Löe plaque index (PI) amounted to
2.29 and approximal plaque index (API) by Lange was
100% [13,14]. It was also found that her tongue tended
to stick to the palate due to saliva hyposecretion. This
condition caused difficulties in eating and bolus forming,
affected her taste perception, and resulted in oversensi-
tivity to the temperature of drunk liquids, as well as
reduced appetite. In addition, the patient complained of
halitosis (fetor ex ore), speaking difficulties, as well as
throat dryness and soreness. The patient underwent sia-
lometry which measured stimulated and unstimulated
saliva secretion. Saliva hyposecretion was diagnosed, and
it amounted to 0.5 ml/min following unstimulated saliva
secretion and to 0.7 ml/min following stimulated saliva
secretion (chewing of a gum). Unstimulated and stimu-
lated saliva secretion was tested threefold within 6 min,
2 h after breakfast. With regards to numerous conditions
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odontal treatment. The treatment involved supra- and
subgingival plaque deposits removal (scaling) together
with periodontal pocket irrigation and root debridement
in order to reduce plaque deposits (bacterial biofilm)
and to accelerate the cell healing process. An invasive
treatment involved teeth 16, 17, and 33 with third degree
root caries, tooth 26 with fourth degree caries, and due
to esthetic reasons, tooth 43 with second degree root
caries. Third degree dental caries were processed and
filled with glass-ionomer cement (Ketac Molar®, 3 M
ESPE, St. Paul, MN, USA). For a deep cavity of tooth 26,
an additional self-hardening calcium hydroxide base
(Life®, Kerr Corporation, Orange, CA, USA) was used.
For esthetic reasons, caries on labial surfaces of teeth 33
and 43 were filled with complex material using the
sandwich technique (Herculite®, Kerr Corporation,
Orange, CA, USA). Following the treatment, the ex-
posed root surfaces of all the teeth were covered with
35% CHX varnish (EC40™ Biodent®, Certichem, Nijmenen,
Netherlands) for preventive reasons. Afterwards, the
patient was once more instructed how to keep good oral
cavity hygiene and how to perform routine oral hygiene
activities correctly. It was recommended that the patient
precisely remove food residues and dental plaque with the
use of a nonabrasive fluoride toothpaste (Elmex, Colgate
GABA Therwill, Switzerland) after each meal, and rinse
her mouth with alcohol-free mouthwashes containing 0.1%
chlorhexidine (Eludril Classic, Pierre Fabre Medicament,
Warsaw, Poland). For xerostomia treatment, a pilocarpine-
based formulation was applied with splitting daily dosage
of 10 mg/day. During policarpine treatment, the patient
was instructed to drink more liquids, in the amount of
2 l/day, to prevent from drug-induced dehydration. Fol-
lowing policarpine treatment and full recovery from the
oral infection and dental caries, it was recommended
that the patient applies artificial saliva based on mucin,
carboxymethylcellulose, and glycerine. In addition to
periodontal treatment, the patient underwent psychi-
atric treatment and participated in psychoeducation on
schizophrenia. Psychiatric treatment involved adminis-
tering olanzapine at a dose of 25 mg/day, which
allowed for improvement in patient’s mental health.
The psychotic symptoms (delusions and hallucinations)
ceased, and cognitive functions returned to normal.
The patient underwent individual cognitive behavioral
therapy (CBT) and participated in psychoeducation.
After 4 weeks, the patient had her oral hygiene status
once more examined with the use of the indexes previously
applied. Silness-Löe plaque index amounted to 0.58 and
approximal plaque index to 23%, which indicated sig-
nificant dental plaque reduction. After 12 weeks, all the
teeth were covered again with 35% CHX varnish
(EC40™ Biodent®, Certichem, Nijmenen, Netherlands).The amount of Streptococcus mutant was significantly
decreased in saliva and dental plaque. Effectiveness of
EC40 was confirmed by the direct contact test (DCT)
(Nunclon Delta Surface; Nunc, Roskilde, Denmark).
The DCT was used to assess the antimicrobial activity
of the CHX varnishes [15].
With regular dental visits, continuous psychiatric care
and participation in psychoeducation, the patient regained
control over her health status and did not feel anxious
about the therapy any more. The patient started compli-
ance with the doctors and began to visit her dentist,
psychiatrist, and psychologist on a regular basis.
Discussion
Saliva is responsible for maintaining homeostasis within
the oral cavity. It protects against mechanical and chemical
injuries and has antibacterial, antifungal, digestive, and
anticarious effects [16].
Saliva secretion disorder may cause excessive mouth
dryness as a result of saliva hyposecretion or salivation
as a result of saliva hypersecretion. Dry mouth, xerostomia
(sialopenia, hypoptyalism, hyposalivation), can be caused
by actual saliva hyposecretion (true xerostomia) or sub-
jective dry mouth sensation (false xerostomia) in people
with normal saliva production. Quantity and composition
of secreted saliva are controlled by the sympathetic and
parasympathetic nervous systems, nerve terminals which
are located in salivary glands [17,18].
Drug-induced side effects are most frequently respon-
sible for saliva secretion disorders [19,20]. In the described
case, the patient reported saliva secretion disorders after
taking antipsychotic drugs, such as aripiprazole, pernazine,
and risperidone. Risperidone not only disturbed saliva
secretion but also caused neuroleptic malignant syndrome,
which is an idiopathic, life-threatening condition mainly
related to the use of antipsychotic drugs. Less common,
but also possible, is NMS, which may appear as a result
of lithium monotherapy or the treatment with antide-
pressants (clomipramine, dezipramine), amantadine,
carbamazepine, L-dopa, anticholinergic agents, ganciclovir,
iron formulations, metoclopramide, as well as oral contra-
ceptives. Neuroleptic malignant syndrome may develop
even after a single dose of the drug which is administered
as premedication before surgery, although within a thera-
peutic range [21]. According to the classification of mental
disorders, Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition, Text Revision (DSM-IV-TR), in
order for NMS to be diagnosed, it is necessary to detect
severe muscle rigidity and high fever directly after the last
dose of antipsychotics has been taken. Also, at least two
additional symptoms are required to occur, such as
diaphoresis, dysphagia, shivering, incontinence, con-
sciousness disturbance - from hypersomnia to coma,
mutism, tachycardia, increased or labile blood pressure,
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(CPK) [22]. Fever, progressing consciousness disturbance,
changes in the autonomic nervous system activity, and
extrapyramidal symptoms in patients treated with antipsy-
chotics indicate that they are developing NMS. In the case
of the described patient, a history of neuroleptic malignant
syndrome was the reason for her discontinuing anti-
psychotic treatment or increasing the medication doses
too rapidly.
Fluctuations in antipsychotic serum levels of the pa-
tient caused xerostomia. Inconsistent daily dosing of
antipsychotics led to stimulation of sympathetic post-
synaptic alpha-1 adrenergic receptors. As a result,
water and electrolytes secretion increased. Beta-1
adrenergic receptors stimulation resulted in elevated
secretion of enzymes and proteins with saliva. Activa-
tion of somatodendritic alpha-2 adrenergic receptors
inhibited saliva secretion. The parasympathetic system is
responsible for regulation of salivary secretion, which con-
trols the process through M1 and M3 muscarinic recep-
tors. Acetylocholine and vasoactive intestinal peptide
released at axon terminals of parasympathetic neurones
increase secretion of water and electrolytes after binding
to muscarinic receptors of secretory cells in the salivary
glands. Activation of the sympathetic nervous system
inhibits the parasympathetic nervous system through
alpha-2 adrenergic receptors in preganglionic parasympa-
thetic neurons and at peripheral terminals of postganglionic
parasympathetic neurones.
Dry mouth occurs during stimulation of the sympathetic
system, e.g., when a patient feels anxiety. This reduces
secretion of serous saliva and stimulates production of
mucous (thick) saliva through activation of stimulating
beta-receptors. Substances affecting the receptors of the
autonomic nervous system disturb saliva secretion. Antago-
nists of alpha-1 adrenergic and muscarinic receptors, ago-
nists of alpha-2 adrenergic receptor, and noradrenaline
reuptake inhibitors cause dry mouth, while antagonists of
alpha-2 receptor and agonists of muscarinic and alpha-1
adrenergic receptors increase saliva secretion [23].
Conclusion
Schizophrenic patients often neglect not only psychiatric
treatment but also their somatic health status. In anti-
psychotic treatment, it is important to detect drug-
induced complications early, which may occur in the form
of saliva secretion disorders, exacerbation of the disease
symptoms, ineffectiveness of the applied pharmacother-
apy, or life-threatening conditions, such as NMS. Schizo-
phrenic patients who have experienced drug-induced
adverse effects may be reluctant to compliance with their
psychiatrist. In addition, side effects of antipsychotics,
including dry mouth, may encourage mentally ill patients
to visit their dentist. Therefore, a good cooperation ofpsychiatrists with other specialists in the scope of treat-
ment for a particular patient not only allows for selection
of the most comprehensive method of treatment yet also
minimises drug-induced adverse effects.
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